Michael Jackson,
Senior Vice President, Drug Discovery and Development, Conrad Prebys Center for Chemical Genomics
Dr. Jackson is responsible for the operations of the Prebys center, a 70-person, multidisciplinary Drug Discovery enterprise, which has the capabilities needed for small molecule drug discovery and drug repositioning. The overall mission is to generate a pipeline of first-in-class drugs based on breakthrough research conducted by investigators at the Institute and their collaborators.
Prior to joining SBP in 2009, Dr. Jackson spent 15 years at Johnson & Johnson developing a track record for research and development, including successfully gaining regulatory approval for several drug delivery products, as he rose through the ranks from Vice President of Discovery to President of R&D at ALZA Corporation. He received his Ph.D. from the Department of Biochemistry at the University of Dundee in Scotland and completed his post-doctoral training at The Scripps Research Institute.
|
|
|
